Jiayu Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jiayu Liu has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Ju Cao
Department of Laboratory Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China
2 shared publications - Xiaofei Lai
Department of Laboratory Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China
2 shared publications - Yi Liu
Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China
2 shared publications Chunxiang Wu
Department of Clinical Laboratory Medicine, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, Chengdu 610072, China
1 shared publicationFang Xu
Department of Critical Care Medicine, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
1 shared publication- Fang Xu
Department of Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
1 shared publication
Latest Publications
- 28 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (834) , eadw8481
Meteorin-like is associated with poor outcome in invasive candidiasis in mouse models and in humans
Invasive candidiasis is a leading cause of nosocomial bloodstream infection associated with high mortality, and there is a pressing need to develop biomarker-guided antifungal therapy to improve clinical outcomes. Meteorin-like (METRNL) is a cytokine that can act as a high-affinity ligand for the stem cell factor receptor KIT; however, the functional role of METRNL in fungal infection remains unclear. Here, we found that METRNL acts as a disease-promoting immune checkpoint to facilitate invasive Candida albicans ( C. albicans ) infection. Mice deficient in METRNL were refractory to a lethal systemic infection with C. albicans. Treatment with a METRNL blocking antibody protected mice from invasive C. albicans infection, whereas treatment with recombinant METRNL or overexpression of endogenous METRNL dampened fungal clearance and aggravated disease mortality but not in mice with macrophage-specific deletion of KIT. The METRNL-KIT axis decreased dectin-1 expression and impaired fungal phagocytosis and killing capacity in macrophages, which was dependent on signal transducer and activator of transcription 3 signaling, thereby negatively regulating host antifungal immunity. In two independent cohorts, patients with candidemia had elevated circulating METRNL concentrations compared with patients with bacteremia or healthy volunteers. In both cohorts, a higher circulating METRNL concentration was associated with poor survival. Therefore, our study provides mechanistic and translational insights into how METRNL orchestrates macrophage-dependent antifungal immunity, implying that a potential theranostic approach involving blood-circulating METRNL-guided patient stratification and targeted therapy of blocking METRNL may help improve the management of human fungal disease through a precision medicine strategy.
- 28 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (834) , eadw8481
Meteorin-like is associated with poor outcome in invasive candidiasis in mouse models and in humans
Invasive candidiasis is a leading cause of nosocomial bloodstream infection associated with high mortality, and there is a pressing need to develop biomarker-guided antifungal therapy to improve clinical outcomes. Meteorin-like (METRNL) is a cytokine that can act as a high-affinity ligand for the stem cell factor receptor KIT; however, the functional role of METRNL in fungal infection remains unclear. Here, we found that METRNL acts as a disease-promoting immune checkpoint to facilitate invasive Candida albicans ( C. albicans ) infection. Mice deficient in METRNL were refractory to a lethal systemic infection with C. albicans. Treatment with a METRNL blocking antibody protected mice from invasive C. albicans infection, whereas treatment with recombinant METRNL or overexpression of endogenous METRNL dampened fungal clearance and aggravated disease mortality but not in mice with macrophage-specific deletion of KIT. The METRNL-KIT axis decreased dectin-1 expression and impaired fungal phagocytosis and killing capacity in macrophages, which was dependent on signal transducer and activator of transcription 3 signaling, thereby negatively regulating host antifungal immunity. In two independent cohorts, patients with candidemia had elevated circulating METRNL concentrations compared with patients with bacteremia or healthy volunteers. In both cohorts, a higher circulating METRNL concentration was associated with poor survival. Therefore, our study provides mechanistic and translational insights into how METRNL orchestrates macrophage-dependent antifungal immunity, implying that a potential theranostic approach involving blood-circulating METRNL-guided patient stratification and targeted therapy of blocking METRNL may help improve the management of human fungal disease through a precision medicine strategy.
- 31 January 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (732) , eadi3275
Bone morphogenetic protein 9 is a candidate prognostic biomarker and host-directed therapy target for sepsis
Defining next-generation immune therapeutics for the treatment of sepsis will involve biomarker-based therapeutic decision-making. Bone morphogenetic protein 9 (BMP9) is a cytokine in the transforming growth factor–β superfamily. Here, circulating BMP9 concentrations were quantified in two independent cohorts of patients with sepsis. Decreased concentrations of serum BMP9 were observed in the patients with sepsis at the time of admission as compared with healthy controls. Concentrations of BMP9 at the time of admission were also associated with 28-day mortality, because patients with sepsis at a higher risk of death had lower BMP9 concentrations. The mechanism driving the contribution of BMP9 to host immunity was further investigated using in vivo murine sepsis models and in vitro cell models. We found that BMP9 treatment improved outcome in mice with experimental sepsis. BMP9-treated mice exhibited increased macrophage influx into the peritoneal cavity and more efficient bacterial clearance than untreated mice. In vitro, BMP9 promoted macrophage recruitment, phagocytosis, and subsequent bacterial killing. We further found that deletion of the type 1 BMP receptor ALK1 in macrophages abolished BMP9-mediated protection against polymicrobial sepsis in vivo. Further experiments indicated that the regulation of macrophage activation by the BMP9-ALK1 axis was mainly mediated through the suppressor of mother against decapentaplegic 1/5 signaling pathway. Together, these results suggest that BMP9 can both serve as a biomarker for patient stratification with an independent prognostic value and be developed as a host-directed therapy for sepsis.
- 31 January 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (732) , eadi3275
Bone morphogenetic protein 9 is a candidate prognostic biomarker and host-directed therapy target for sepsis
Defining next-generation immune therapeutics for the treatment of sepsis will involve biomarker-based therapeutic decision-making. Bone morphogenetic protein 9 (BMP9) is a cytokine in the transforming growth factor–β superfamily. Here, circulating BMP9 concentrations were quantified in two independent cohorts of patients with sepsis. Decreased concentrations of serum BMP9 were observed in the patients with sepsis at the time of admission as compared with healthy controls. Concentrations of BMP9 at the time of admission were also associated with 28-day mortality, because patients with sepsis at a higher risk of death had lower BMP9 concentrations. The mechanism driving the contribution of BMP9 to host immunity was further investigated using in vivo murine sepsis models and in vitro cell models. We found that BMP9 treatment improved outcome in mice with experimental sepsis. BMP9-treated mice exhibited increased macrophage influx into the peritoneal cavity and more efficient bacterial clearance than untreated mice. In vitro, BMP9 promoted macrophage recruitment, phagocytosis, and subsequent bacterial killing. We further found that deletion of the type 1 BMP receptor ALK1 in macrophages abolished BMP9-mediated protection against polymicrobial sepsis in vivo. Further experiments indicated that the regulation of macrophage activation by the BMP9-ALK1 axis was mainly mediated through the suppressor of mother against decapentaplegic 1/5 signaling pathway. Together, these results suggest that BMP9 can both serve as a biomarker for patient stratification with an independent prognostic value and be developed as a host-directed therapy for sepsis.